[HTML][HTML] High-efficacy therapies for treatment-naïve individuals with relapsing–remitting multiple sclerosis
L Freeman, EE Longbrake, PK Coyle, B Hendin… - CNS drugs, 2022 - Springer
There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …
action currently approved by the US Food and Drug Administration for the treatment of …
[HTML][HTML] Brain health: time matters in multiple sclerosis
Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a …
JF Foley, G Defer, LZ Ryerson, JA Cohen… - The Lancet …, 2022 - thelancet.com
Background Treatment with natalizumab once every 4 weeks is approved for patients with
relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal …
relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal …
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
CS Constantinescu, N Farooqi… - British journal of …, 2011 - Wiley Online Library
Experimental autoimmune encephalomyelitis (EAE) is the most commonly used
experimental model for the human inflammatory demyelinating disease, multiple sclerosis …
experimental model for the human inflammatory demyelinating disease, multiple sclerosis …
Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort
Importance With multiple and increasingly effective therapies for relapsing forms of multiple
sclerosis (MS), disease-free status or no evidence of disease activity (NEDA) has become a …
sclerosis (MS), disease-free status or no evidence of disease activity (NEDA) has become a …
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity'(NEDA-4) in relapsing–remitting multiple sclerosis
Background:'No evidence of disease activity'(NEDA), defined as absence of magnetic
resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and …
resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and …
Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
D Ontaneda, E Tallantyre, T Kalincik… - The Lancet …, 2019 - thelancet.com
Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …
modifying therapies with diverse safety and efficacy profiles. The importance of early …
[HTML][HTML] Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis
EA Mills, MA Ogrodnik, A Plave… - Frontiers in neurology, 2018 - frontiersin.org
Dimethyl fumarate (DMF) is an effective treatment option for relapsing–remitting multiple
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …
[HTML][HTML] Outcome measures in clinical trials for multiple sclerosis
CEP van Munster, BMJ Uitdehaag - CNS drugs, 2017 - Springer
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
[HTML][HTML] Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
G Giovannoni, B Turner, S Gnanapavan… - Multiple sclerosis and …, 2015 - Elsevier
The management of multiple sclerosis is becoming increasingly complex with the
emergence of new and more effective disease-modifying therapies (DMT). We propose a …
emergence of new and more effective disease-modifying therapies (DMT). We propose a …